68 results about "During menopause" patented technology

The invention belongs to the field of biological medicines, and particularly discloses a mesenchymal stem cell and cytokine preparation having treatment effects on premature ovarian failures and perimenopausal syndromes, and a preparing method for the preparation. The preparation is composed of umbilical cord or placenta mesenchymal stem cells and cytokines, as well as hyaluronate which is used for bearing the umbilical cord or placenta mesenchymal stem cells and cytokines and has the slow-release and anti-inflammatory effects; and the preparation is injected into a part of the endometrium and ovary in a targeted manner to be slowly released and absorbed. The curative effect of repairing the ovary and endometrium can be achieved, functional ovulation can be promoted, the premature ovarian failures can be treated, and the various perimenopausal syndromes can be remitted. Compared with an existing intravenous re-transfusion and intervention path, untoward effects of intravenous transfusion are avoided through the preparation and a using method of the preparation, abdomen and local wounds caused by interventional treatment are avoided, and side effects and hurts caused by treatment to a patient can be effectively prevented, so that the preparation is safer and more effective, is high in practicability and easy to popularize, and has the huge application value.

The present invention is directed to a method of treating, preventing, or reducing the risk of bone deterioration or osteoporosis in a peri- or post-menopausal female subject. The method involves selecting a peri- or post-menopausal female subject in need of treating, preventing, or reducing the risk of bone deterioration or osteoporosis and administering hepcidin to the selected subject under conditions effective to treat, prevent, or reduce the risk of bone deterioration or osteoporosis.

The invention relates to a Chinese medicament health product for supplementing female hormone for women during menopause. The Chinese medicament health product comprises the oral medication raw materials of epimedium herb, radix paeoniae alba, raspberry, motherwort, angelica sinensis, fructus corni, yerbadetajo herb, polygala, wolfberry fruit, placenta hominis, fructus ligustri lucidi, radix polygoni multiflori, dodder, broomrape, semen boitae, rhizoma anemarrhenae, mulberries, rhizoma curculiginis, prepared rhizome of rehmannia, semen zizyphi spinosae, rhizoma cyperi, fructus tritici levis, tuckahoe, Chinese dage and flos albiziae, and external-use raw materials of common cnidium fruit, rhizoma ligustici wallichii, epimedium herb, caulis spatholobi, cortex albiziae, phellodendron bark, red sage root, tuber fleeceflower stem, mother-of-pearl, red raspberry and herba leonuri. The Chinese medicament health product can stimulate adrenal hyperblastosis, improve the level of female hormone, obviously adjust the vegetative nerve function, reduce endocrine disequilibrium, improve psychataxia and maintain homergy, and all the medicaments are compatible with one another to achieve effects of warming the kidney, benefiting yin, and regulating and tonifying yin and yang.

The present invention is directed to a method of treating, preventing, or reducing the risk of bone deterioration or osteoporosis in a peri- or post-menopausal female subject. The method involves selecting a peri- or post-menopausal female subject in need of treating, preventing, or reducing the risk of bone deterioration or osteoporosis and administering hepcidin to the selected subject under conditions effective to treat, prevent, or reduce the risk of bone deterioration or osteoporosis.

The invention discloses an active part of Sambucus williamsii Hance with the effect of reducing bone mass loss after menopause. The active part has definite chemical components and mainly comprises seven compounds: vanillic acid, coniferol, levo erythro form guaiacyl glycerol-beta-O-4'-coniferyl alcohol ether, dextro threo form-1-(4-hydroxy-3-methoxyphenyl)-2-[-4-(3-hydroxypropyl)-2-hydroxyphenoxy]-1,3-propanediol, dextro threo form guaiacyl glycerol-beta-O-4'-coniferyl alcohol ether, coniferyl alcohol dehydrogenase and dihydro-coniferyl alcohol dehydrogenase. The active part can remarkably reduce the bone loss of ovariectomized mice, increase bone density of thighbone and shinbone, increase bone volume, does not increase the weight of uterus, and is a component for safely and effectivelyrelieving and improving various symptoms of the bone-related diseases of the menopausal women. The invention has the advantages of providing the active part of the Sambucus williamsii Hance which canbe used for preparing a medicament, food or a food additive for preventing and treating the bone-related diseases after menopause.

The invention discloses an application of catalpol in preparing ovarian aging resisting medicaments. The catalpol can treat various ovarian aging diseases, and particularly has obvious effects on polycystic ovarian syndrome, dysfunctional uterine bleeding, premature ovarian failure or menopause syndrome and the like. According to the application, the catalpol is prepared into oral medicaments, transdermal medicaments or injections for treating ovarian failure diseases.

Pharmaceutical compositions comprising azelastine or a pharmaceutically acceptable salt of azelastine and alprazolam are disclosed. Methods of using the pharmaceutical compositions for treating perimenopausal or menopausal patients, such as patients suffering from, experiencing, exhibiting and / or having one or more symptoms of anxiety or depression, are also disclosed.

Disclosed is a medicinal composition and method of use comprising topiramate for treating hot flashes and excessive sweating known as vasomotor symptoms related to perimenopausal or menopausal symptoms and in a still further embodiment of the invention topiramate and the medicine for treating menopause and perimenopause are provided in a kit or in unit dosage form, e.g., tablet or capsule. As a further embodiment of this invention, topiramate may be administered along with a medicament use to treat hot flashes and excessive sweating related to perimenopausal or menopausal symptoms.

The invention provides an extract for truffles in a hydrophilic solvent. The exact serves as an active ingredient for and is used in the preparation of drugs for preventing and treating women's hormonal imbalance, perimenopause syndrome, senile urethritis and sleep disorder, or food or health care food for improving the related functions.

The invention discloses a medicinal composition for treating vaginal dryness. The composition comprises 50-80 wt% of Oviductus Ranae, and 20-50 wt% of Chinese herbal powder. The medicinal composition has effects in invigorating kidney and vital essence, nourishing Yin and blood, promoting qi circulation to remove stagnation; and can be used for treating symptoms such as vaginal dryness, sexual pain and sexual hypoactivity due to perimenopause or ovary dysfunction. The composition is simple in formula and production, and effective in curative effect, is prepared from pure Chinese medicinal materials, and has no toxic and side effects.

The invention provides medicaments comprising an oenothein, including oral formulations to treat inflammation or to treat hormone balance in perimenopausal, menopausal and postmenopausal women. The oenothein for use in such formulations such as oenothein A or oenothein B maybe purified from natural sources, such as Epilobium.

A product for treating conditions and / or symptoms associated with women health is described, which product comprises at least one cannabinoid in a specific amount, a primary terpene in a specific amount, at least 5% by weight of a non-cannabinoid, non-terpene, carrier, optionally at least three secondary terpenes, and optionally at least one phytoestrogen; wherein said non-cannabinoid, non-terpene carrier comprises cellulose and the terpenes to cannabinoids weight / weight ratio in said product is about 0.1 to about 1.0. Also described is the product wherein said non-cannabinoid, non-terpene carrier comprises less than 5% by weight cellulose and the terpenes to cannabinoids weight / weight ratio in said compositions is about 0.05 to about 1.0, forming a terpene-enriched product. Also described are uses of the product for treating conditions and / or symptoms associated with perimenopause, menopause, female urogenital or reproductive system infections and / or disorders, menstrual cycle, hormonal deficiency and / or hormonal imbalance.

The present invention relates to pharmaceutical compositions comprising ospemifene or a pharmaceutically acceptable salt thereof prepared by direct compression process. The compositions of the invention may be advantageously used for the treatment or prevention of atrophy-related diseases or disorders in women, especially in women during or after the menopause.

The present invention provides transmucosal pharmaceutical or nutraceutical compositions and methods for enhancing transmucosal delivery of pharmaceutical and nutraceutical ingredients through use of methylsulfonylmethane (MSM) as a transmucosal delivery enhancer. In particular, the invention provides transmucosal compositions comprising an active agent selected from a non-steroid anti-inflammatory drug (NSAID); an analgesic; a migraine medication; a menopause medication; a sleep disorder medication; an erectile dysfunction medication, an appetite suppressant, a vitamin, a food supplement and a macromolecule. In certain particular exemplary formulations the appetite suppressant is DL-phenylalanine, and the vitamin is B12.

The invention discloses a traditional Chinese medicine for treating depression. The prescription of the present invention is composed of Cyperus cyperi, vinegar-roasted Bupleurum, turmeric, woody fragrance, Albizia julibrissin, angelica, white peony root, Ophiopogon japonicus, jujube seed, cooked notoginseng, Digupi, Atractylodes macrocephala, Poria cocos, Chuanxiong, Magnolia officinalis, Salvia, bergamot, agrimony, gentian, borneol, licorice and other 21 pure herbal medicines. The whole formula regulates the heart, liver and spleen, treats qi and blood, regulates qi and promotes qi, activates blood to remove blood stasis, calms the nerves and relieves depression. Combination of various medicines, multi-drug coordination has the characteristics of many components and many action links, can work through multiple links, and has a coordinated effect. It is mainly used for the treatment of depression, women's perimenopausal syndrome and menopausal syndrome. The prescription of the present invention is reasonable, and is especially suitable for depression of different genders and age groups. The price is low, the curative effect is good, and there is no toxic or side effect.

The present invention relates to a composition, for preventing, remedying or treating female climacteric syndrome, containing loganin, a derivative of same or pharmaceutically acceptable salts of sameas an active ingredient. Loganin, according to the present invention, enables an increase in the estradiol (17beta-estradiol, E2) concentration in the blood of a menopausal mouse model and has showneffects such as: an increase in the estrogen receptor alpha expression in the uterus; remedying of uterine contraction and degeneration; a decrease in the size and accumulation of adipocytes in the abdominal adipose tissues and the liver; and weight loss. Therefore, loganin enables remedying of symptoms in menopausal women such as loss of estrogen, weight gain, and size increase in adipocytes andfat accumulation in the abdominal adipose tissues and the liver. Therefore, loganin and a composition comprising same as an active ingredient, according to the present invention, are expected to be utilized as a pharmaceutical preparation for preventing and remedying climacteric symptoms.

The present disclosure is directed to generally methods and / or compositions for treating mammographic breast density and / or breast stiffness in a patient in need thereof, such as a pre-menopausal, a peri-menopausal or a post-memopausal patient, comprising the administration of an effective amount of androgenic agent and an effective amount of an aromatase inhibitor. The present disclosure is also directed to methods and / or compositions for reducing breast pain. The present disclosure is also directed to method and / or compositions for reducing elasticity and / or decreasing mechano-transduction on the genome of breast cells. The present disclosure is also directed to methods and / or compositions for stabilizing and / or increasing the levels of androgen receptor expression in breast tissue.

The invention provides a traditional Chinese medicine used for treating menopausal palpitation. The traditional Chinese medicine is prepared from the following medicines: gambir plant, blighted wheat, prepared rhizome of rehmannia, Indian bread, asiatic cornelian cherry fruit, Chinese yam, tree peony root bark, curculigo orchioides, herba epimedii, cassia twig, radix glycyrrhizae preparata, safflower carthamus, India madder root, snake gourd fruit, bamboo shavings, processed rhizoma pinelliae and dried tangerine peel. 700ml of water is added to first dose of the medicines to decoct the medicines until the decoction is 200ml, and 500ml of water is added to second dose of the medicines to decoct the medicines until the decoction is 200ml. The traditional Chinese medicine is taken twice a day on an empty stomach, once in the morning and once in the evening.

The invention relates to at least one probiotic strain chosen from Lactobacillus paracasei 8700:2 (DSM 13434) and / or at least one probiotic strain of Lactobacillus piantarum, for use in the treatment and / or prevention of trabecular bone loss, in a mammal, preferably in anon-rodent mammal, more preferably in a human, most preferably in a peri-menopausal woman, post-menopausal woman or a woman six years or less after onset of menopause.

The present invention relates to: a novel Lactobacillus intestinalis YT2 strain (deposition number: KCCM11812P); and a composition for preventing, alleviating, or treating menopause, comprising, as an active ingredient, Lactobacillus intestinalis comprising the novel strain. The present inventors have established an animal model for menopause through ovariectomy, confirmed changes of the distribution of intestinal microorganisms by the model, identified and isolated a novel Lactobacillus intestinalis strain among lactic acid bacteria of which the distribution is significantly reduced in the menopausal model, and confirmed effects, by means of the novel strain and previously reported Lactobacillus intestinalis strains, of alleviating menopausal symptoms, such as the inhibition of an increase in body fat, the inhibition of a decrease in bone mineral density, the inhibition of an increase in the pain sensitivity, and the alleviation of depression. Therefore, it is expected that the composition comprising the Lactobacillus intestinalis according to the present invention can be usable for a use of preventing, alleviating, or treating menopause.

The invention discloses an application of morindone in preparation of anti-ovarian senescence drugs. The morindone has a remarkable effect on treating various ovarian recession diseases such as polycystic ovarian syndrome, dysfunctional uterine bleeding, premature ovarian failure or menopausal syndrome by up-regulating the protein levels of c-fos mRNA and expression products thereof. According tothe invention, the morindone is prepared into oral administration, transdermal administration or injection administration for treating ovarian recession diseases.

The invention discloses an application of phellinus lonicericola or an extract thereof to the preparation of drugs or healthcare products for regulating estrogens and treating perimenopausal syndrome. The invention also provides a new application of a compound hispolon. The phellinus lonicericola and the extract thereof or the compound hispolon can be combined with estrogen receptors to doubly regulate the estrogens and has the function of promoting the secretion of endogenous estrogens when the endogenous estrogens are insufficient; by using the phellinus lonicericola and the extract thereof or the compound hispolon for treatment, various symptoms and signs can be effectively relieved, the function of slowing down the occurrence and the development of the long-term symptoms such as osteoporosis, cardiovascular disease and the like is provided, the quality of life of the perimenopausal syndrome women can be improved and a new way is developed to treat the perimenopausal syndrome.

The invention provides a compound preparation, which is applied to prevention and / or treatment of female perimenopausal urogenital syndrome and comprises the following main components: epidermal growth factors, sea buckthorn seed oil and glycerol. The invention further provides novel application of the compound preparation, namely application of the compound preparation in prevention and / or treatment of the female perimenopausal urogenital syndrome and application of the compound preparation in products of the female perimenopausal urogenital syndrome. Application in preventing and / or treating female vaginal atrophy, maintaining the state of sexual organs and in products thereof; the invention also relates to an application in prevention and / or treatment of urination disorders such as abnormal urination function, frequent urination, urgent urination and increased nocturnal urination in the perimenopausal period of women and an application in products thereof, and an application in improvement of sex hormone level in the perimenopausal period of women, regulation and recovery of disordered menstrual cycle of women and an application in products thereof. The application provides a basis for preventing and treating the perimenopausal urogenital syndrome by directly utilizing the compound preparation.

The invention discloses an application of fagomine in preparation of an anti-ovarian senescence drug. The fagomine has a remarkable effect on treating various ovarian recession diseases such as polycystic ovarian syndrome, dysfunctional uterine bleeding, premature ovarian failure or menopausal syndrome by up-regulating the protein levels of c-fos mRNA and expression products thereof. The fagomineis prepared into oral administration, transdermal administration or injection administration for treating ovarian recession diseases.

The present invention provides methods to reduce the number and severity of hot flashes utilizing tocotrienols. In particular, symptoms of perimenopause and menopause may be treated using the present methods. The present invention also provides methods to increase tissue concentrations of tocotrienols.

Methods for treating uterine fibroids, endometriosis, adenomyosis, or heavy menstrual bleeding in a subject, which include administering to the subject from 10 mg to 60 mg per day of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea, and from 0.01 mg to 5 mg per day of a hormone replacement medicament. The present disclosure has methods for reducing menstrual bleeding in a subject, reducing bone mineral density loss in a subject caused by administering a GnRH antagonist to the subject, suppressing sex hormones in a subject, reducing vasomotor symptoms or hot flashes in a subject, and reducing symptoms of decreased libido in a subject having uterine fibroids, endometriosis, or adenomyosis. Further provided are methods of maintaining blood glucose profile, maintaining lipid profile, and / or maintaining bone mineral density in a pre-menopausal woman being treated for one or moreconditions or symptoms of endometriosis, adenomyosis, uterine fibroids, or heavy menstrual bleeding; and methods of contraception and treating infertility.

The invention provide a 3D printed artificial ovarium biological stent capable of activating an original ovarian follicle. According to the 3D printed artificial ovarium biological stent, a 3D printing technology is utilized to mix an original ovarian follicle activating agent and hormones and growth factors which can promote the developing of the ovarian follicle into a stent material to be molded through printing, an ovarian cortex fragment which contains the original ovarian follicle is transplanted, after the cortex fragment is transplanted back to the body, the cortex fragment can achievebetter stent protection and more diversified nutrient supplying, the biological stent is gradually degraded in the body to sustainably release the ovarian follicle activating agent, and therefore theoriginal ovarian follicle is sustainably activated. The stent has the advantages that the in vitro activating time of the original ovarian follicle is greatly reduced, a novel researching tool is provided for an revealing an original ovarian follicle activating mechanism, the waiting time of the patient is reduced on the basis that secondary surgery is avoided, and a novel choice is provided forthe clinical treatment of premature ovarian failure and an assisted reproduction technology; after the ovarian follicle is activated, a large number of hormones are secreted to regulate the secretionin the body, and a novel researching direction is provided for improving comprehensive symptoms of menopause and ageing slowing.